RESUMO

BACKGROUND: Population-based cancer registry (PBCR) data provide crucial information for evaluating the effectiveness of cancer services and reflect prospects for cure by estimating population-based cancer survival. This study provides long-term trends in survival among patients diagnosed with cancer in the Barretos region (São Paulo State, Brazil). METHODS: In this population-based study, we estimated the one- and five-year age-standardized net survival rates of 13,246 patients diagnosed with 24 different cancer types in Barretos region between 2000 and 2018. The results were presented by sex, time since diagnosis, disease stage, and period of diagnosis. RESULTS: Marked differences in the one- and five-year age-standardized net survival rates were observed across the cancer sites. Pancreatic cancer had the lowest 5-year net survival (5.5 %, 95 %CI: 2.9-9.4) followed by oesophageal cancer (5.6 %, 95 %CI: 3.0-9.4), while prostate cancer ranked the best (92.1 %, 95 %CI: 87.8-94.9), followed by thyroid cancer (87.4 %, 95 %CI: 69.9-95.1) and female breast cancer (78.3 %, 95 %CI: 74.5-81.6). The survival rates differed substantially according to sex and clinical stage. Comparing the first (2000-2005) and last (2012-2018) periods, cancer survival improved, especially for thyroid, leukemia, and pharyngeal cancers, with differences of 34.4 %, 29.0 %, and 28.7 %, respectively. CONCLUSION: To our knowledge, this is the first study to evaluate long-term cancer survival in the Barretos region, showing an overall improvement over the last two decades. Survival varied by site, indicating the need for multiple cancer control actions in the future with a lower burden of cancer.

Assuntos

RESUMO

Background: In Brazil, there is a higher prevalence of Li-Fraumeni Syndrome (LFS) compared to worldwide, due to the founder mutation in the TP53 gene p.R337H. However, a large portion of the population, that depends on National Health Care System, does not have access to effective screening through the Toronto Protocol guidelines that enables early diagnosis and improves overall survival. Population strategies for early cancer detection recommended in Brazil are limited and additional screening is not offered to patients at a high risk, leading to late diagnoses and higher cancer mortality. This study aims to assess the cost-effectiveness of introducing annual screening that follows the Toronto Protocol for patients diagnosed with LFS in Brazil. Methods: A Markov decision analytic model was developed to estimate cost-effectiveness of 1,000 LFS carriers under surveillance and non-surveillance strategies over a patient's lifetime. The main outcome was the incremental cost-effectiveness ratio (ICER), expressed as cost per additional life year gained, comparing surveillance and non-surveillance strategies in p.R337H TP53 carriers. Findings: For females, the model showed a mean cost of $2,222 and $14,640 and yielded 22 and 26·2 life years for non-surveillance and surveillance strategies, respectively. The ICER for early cancer surveillance versus no surveillance was $2,982 per additional life year gained. For males, the model predicts mean lifetime costs of $1,165 and $12,883 and average life years of 23·5 and 26·3 for non-surveillance and surveillance strategies, respectively. This amounts to an ICER of $ 4,185 per additional life year. Surveillance had 64% and 45% probabilities of being the most cost-effective strategy for early cancer detection in female and male carriers, respectively. Interpretation: The adoption of surveillance for patients diagnosed with LFS by the Brazilian National Health Care System is cost-beneficial for both males and females. Funding: This research received no specific grant from any funding agency.

Introdução: No Brasil, há uma maior prevalência da Síndrome de Li-Fraumeni (LFS) em comparação ao mundo, devido à mutação fundadora no gene TP53 p.R337H. No entanto, uma grande parte da população brasileira, que depende do Sistema Único de Saúde (SUS), não tem acesso a um rastreamento eficaz através das diretrizes do Protocolo de Toronto, que possibilitam o diagnóstico precoce e ganho em sobrevida dos portadores da síndrome. As estratégias populacionais para detecção precoce do câncer recomendadas no Brasil são limitadas e o rastreamento adicional não é oferecido a pacientes de alto risco, levando a diagnósticos tardios e maior mortalidade por câncer. Este estudo tem como objetivo avaliar a relação custo-efetividade do rastreamento anual, conforme o Protocolo de Toronto, para pacientes diagnosticados com LFS no Brasil. Métodos: Foi desenvolvido o modelo analítico de decisão Markov para estimar a relação de custo-efetividade de 1.000 portadores da LFS sob estratégias de vigilância e de não-vigilância durante a vida útil do portador. O principal desfecho é a razão de custo-efetividade incremental (ICER), que expressa qual o custo adicional por ano de vida ganho, comparando as estratégias de vigilância e não-vigilância em portadores da mutação p.R337H TP53. Resultados: Para as mulheres, o modelo demonstrou o custo médio de $2.222 e $14.640 e resultou em 22 e 26·2 anos de vida útil para as estratégias de vigilância e não-vigilância, respectivamente. O ICER para rastreamento precoce do câncer versus nenhum rastreamento foi de $2.982 por ano de vida adicional ganho. Para os homens, o modelo prevê custos médios de vida de US$ 1.165 e US$ 12.883 e anos de vida médios de 23·5 e 26·3 anos para estratégias de vigilância e não-vigilância, respectivamente. Isto equivale a um ICER de US$ 4.185 por ano de vida adicional ganho. A realização do rastreamento conforme o Protocolo de Toronto tem probabilidades de 64% e 45% de ser a estratégia mais custo-efetiva para a detecção precoce do câncer em portadores do sexo feminino e masculino, respectivamente. Interpretação: A adoção do rastreamento para pacientes diagnosticados com LFS pelo Sistema Único de Saúde Brasileiro é custo-efetiva tanto para portadores do sexo masculino quanto feminino. Financiamento: Esta pesquisa não recebeu nenhum subsídio específico de nenhuma agência de financiamento.

RESUMO

OBJECTIVE: To evaluate the descriptive epidemiology of pediatric cancers among Alaska Native people. STUDY DESIGN: We used data from the Alaska Native Tumor Registry, a population-based registry capturing cancer information among Alaska Native people 1969-present. Specifically, we examined all cases of cancer diagnosed among individuals ages 0-19 years. Cases were classified according to the International Classification of Childhood Cancers, 3rd edition (ICCC-3). We estimated incidence and distribution of cases by ICCC-3 cancer site, comparing between the time periods 1969-1996 and 1997-2016. We assessed 12-month and 5-year cause-specific survival, and examined differences over the time period, adjusted for age, sex, and ICCC-3 site. RESULTS: Incidence rates of pediatric cancers increased between 1969 and 1996 (n = 134) and 1997 and 2016 (n = 186) among Alaska Native people, from 139.8 in 1 000 000 (95% CI, 116.99-165.7) to 197.54 in 1 000 000 (95% CI, 170.1-228.1). Distribution of ICCC-3 sites differed between time periods (P < .0001). Finally, cancer survival was high; the 12-month survival probability from all ICCC-3 sites combined was 0.88 (95% CI, 0.84-0.92) and the 5-year survival probability was 0.76 (95% CI, 0.70-0.81) for 1969-2016. After adjusting for age, sex, and ICCC-3 site, we observed a 57% decrease in the risk of death when comparing Alaska Native pediatric cancer cases diagnosed in 1997-2016 with those diagnosed in 1969-1996. CONCLUSIONS: This information will be of value for our understanding of pediatric cancers among Indigenous peoples of the US, and will also be informative for clinicians providing care to this population.

Assuntos

RESUMO

OBJECTIVES: Delivering health care timely and geographically accessible are determining factors for the prognosis of children with cancer. This study analyzed geographic access and timeliness to diagnostic services in Colombia. METHODS: In this Colombian national childhood cancer database-based study, patients and their diagnostic facilities were individually and separately space positioned. Distances between the household to the diagnostic facility, and between the clinical date of suspicion and diagnosis were determined. Using exploratory data analysis, we obtained a probability density function (lambda), which expressed a correlation percentage between the residential location of the patient and either travel time or timeliness of treatment. RESULTS: 27 % of the sample of 731 patients had access to diagnostic centres in less than 30 min. The travel-distance to diagnostic centres was lowest in the Caribe and Andina Regions (43 % and 32 % distances up to 30 km respectively). However, in Amazonía and Orinoquía Regions, 87 % and 81 % had to travel more than 90 km - representing very long travel times. For more than 23 % of patients, time to diagnosis was more than 90 days, in Orinoquía, this was above 90 days for 1/3 of patients. Despite relatively short travel distances in the Caribe-Region, for 61 % time to diagnosis exceeded 30 days. CONCLUSIONS: This study identified clear shortcomings in the Colombian Health System related to the quality of childhood cancer-related health care in terms of timeliness, cancer networks, and geographic access. These inequities not only depend on sociodemographic-characteristics and should be intervened upon.

Assuntos

RESUMO

BACKGROUND: Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to examine incidence and mortality patterns and trends in TT. METHODS: Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer Registry (population-based cancer registry of TT) between 1995 and 2009 were analyzed. Age-standardized rates, overall and by sex, ancestry, and geography, were reported. RESULTS: The highest incidence and mortality rates were observed for cancers related to reproductive organs in women, namely, breast, cervical, and uterine cancers, and prostate, lung and colorectal cancers among men. Average incidence rates were highest in areas covered by the Tobago Regional Health Authority (TRHA) (188 per 100,000), while average mortality rates were highest in areas covered by the North West Regional Health Authority (108 per 100,000). Nationals of African ancestry exhibited the highest rates of cancer incidence (243 per 100,000) and mortality (156 per 100,000) compared to their counterparts who were of East Indian (incidence, 125 per 100,000; mortality, 66 per 100,000) or mixed ancestry (incidence, 119 per 100,000; mortality, 66 per 100,000). CONCLUSIONS: Our findings highlight the need for national investment to improve the understanding of the epidemiology of cancer in Trinidad and Tobago, and to ultimately guide much needed cancer prevention and control initiatives in the near future.

Assuntos

RESUMO

Cancer research has a great importance across the world. It is responsible for data analysis of cancer incidence by region, ethnicity, gender, age, social and economic issues, and contributes to the assessment of population health necessities. Nowadays, Brazil has a complex cancer care scenario. There are nearly 600.000 new cancer cases each year. Cancer surveillance in Brazil is carried out by a network of cancer registries which together feed the data warehouse of cancer incidence across the country. The analysis of cancer data warehouses using Data Mining techniques may discover hidden relations among patients' data, cancer treatment, and disease surveillance. This paper presents the development of a Big Data project with the purpose to analyze the cancer incidence and mortality patterns within the different regions and population groups in Brazil.

Assuntos

RESUMO

BACKGROUND: The benefit of surveillance after curative cystectomy in bladder cancer is unproven, but might be justified if detection of asymptomatic recurrence improves survival. Previous studies showing a benefit of surveillance might have been affected by lead-time or length-time bias. MATERIALS AND METHODS: We conducted a retrospective cohort study among 463 cystectomy patients at the University of Pennsylvania. Patients were followed according to a standardized protocol and classified according to asymptomatic or symptomatic recurrence detection. Primary outcome was all-cause mortality. Adjusted Cox regression models were used to assess the effect of mode of recurrence on survival from time of cystectomy (model 1) and time of recurrence (model 2) to account for lead and length time. RESULTS: One hundred ninety-seven patients (42.5%) recurred; 71 were asymptomatic (36.0%), 107 were symptomatic (54.3%), and 19 (9.6%) were unknown. Relative to patients with asymptomatic recurrence, patients with symptomatic recurrence had significantly increased risk of death (model 1: hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.07-2.61; model 2: HR, 1.74, 95% CI, 1.13-2.69) and had lower 1-year overall survival from time of recurrence (29.37% vs. 55.66%). Symptomatic patients were diagnosed with recurrence a median of 1.7 months before asymptomatic patients, yet their median survival from recurrence was 8.2 months less. CONCLUSION: Symptomatic recurrence is associated with worse outcomes than asymptomatic recurrence, which cannot be explained by lead- or length-time bias. Similar methods to account for these biases should be considered in studies of cancer surveillance. Shortening surveillance intervals might allow for detection of more recurrences in an asymptomatic phase.

Assuntos

RESUMO

Las enfermedades inflamatorias intestinales representan una patología de alta morbilidad. Esto debido a que se asocia a mayor su riesgo de desarrollo de neoplasias tanto colorrectales como colangiocarcinoma, desarrollo de complicaciones como fístulas, abscesos, estenosis intestinales espontáneas o postoperatorias y estenosis biliares en aquellas asociadas a colangitis esclerosante primaria. El rol del endoscopista avanzado en este grupo de pacientes se encuentra en la vigilancia de ambas neoplasias y en el tratamiento endoscópico de las complicaciones ya mencionadas. En relación a la vigilancia de cáncer colorrectal, existen distintas recomendaciones internacionales respecto a los intervalos y las técnicas de vigilancia, situándose la cromoendoscopia como método de elección emergente en los últimos años. Es importante destacar la publicación del uso de nueva nomenclatura para los hallazgos colonoscópicos durante la vigilancia del cáncer colorectal, abandonando los conceptos de DALM o lesiones o masas asociadas a displasia, lesiones tipo adenoma o no adenomatosas.

Inflammatory bowel diseases represent a high morbidity pathology given their high risk of developing both colorectal cancer and cholangiocarcinoma, besides the development of fistulas, abscesses, spontaneous or postoperative intestinal stenosis and biliary strictures in patients diagnosed with primary sclerosant cholangitis. The advanced endoscopist's rol in this group of patients lies within surveillance of both neoplasms and the endoscopic treatment of complications already mentioned. In relation to surveillance of colorectal cancer, there are various international recommendations regarding surveillance intervals and techniques, with chromoendoscopy emerging as a method of choice in recent years. It is important to highlight the use of new nomenclature for colonoscopic findings during surveillance, abandoning concepts as DALM, adenoma-like lesions or non adenoma-like lesions.

Assuntos